Details for New Drug Application (NDA): 217230
✉ Email this page to a colleague
NDA 217230 describes RUFINAMIDE, which is a drug marketed by Alkem Labs Ltd, Aurobindo Pharma, Bionpharma, Chartwell Rx, Hetero Labs Ltd Iii, Hikma, Lupin Ltd, Glenmark Pharms Ltd, Micro Labs, and Mylan, and is included in fourteen NDAs. It is available from ten suppliers. Additional details are available on the RUFINAMIDE profile page.
The generic ingredient in RUFINAMIDE is rufinamide. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the rufinamide profile page.
The generic ingredient in RUFINAMIDE is rufinamide. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the rufinamide profile page.
Summary for 217230
| Tradename: | RUFINAMIDE |
| Applicant: | Aurobindo Pharma |
| Ingredient: | rufinamide |
| Patents: | 0 |
Suppliers and Packaging for NDA: 217230
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| RUFINAMIDE | rufinamide | TABLET;ORAL | 217230 | ANDA | Aurobindo Pharma Limited | 59651-616 | 59651-616-08 | 120 TABLET, FILM COATED in 1 BOTTLE (59651-616-08) |
| RUFINAMIDE | rufinamide | TABLET;ORAL | 217230 | ANDA | Aurobindo Pharma Limited | 59651-617 | 59651-617-08 | 120 TABLET, FILM COATED in 1 BOTTLE (59651-617-08) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 200MG | ||||
| Approval Date: | Jun 16, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 400MG | ||||
| Approval Date: | Jun 16, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
